+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID03977571

NORDIC-SUN Trial Comparing Deferred Kidney Surgery Versus No Surgery in Patients with Metastatic Renal Cell Carcinoma Receiving Immunotherapy

Led by Niels Fristrup · Updated on 2026-09-23

400

Participants Needed

11

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the role of deferred cytoreductive nephrectomy compared with no surgery in patients with synchronous metastatic renal cell carcinoma mRCC who have intermediate or poor risk features according to the International Metastatic Renal Cell Carcinoma Database Consortium IMDC. The study evaluates the impact of surgery timing after initial treatment with immune checkpoint inhibitors, such as nivolumab combined with ipilimumab, or a tyrosine kinase inhibitor TKI combined with immunotherapy, aiming to improve overall survival in this patient group. Participants receive induction immunotherapy immediately after enrollment, consisting of four series of nivolumab combined with ipilimumab or a TKIIO combination over three months. After this induction, patients are assessed for eligibility for surgery by a multidisciplinary team. Those with three or fewer IMDC risk factors and deemed suitable for surgery are randomized to either deferred nephrectomy followed by maintenance therapy or maintenance therapy alone. Patients not eligible for surgery or with more than three risk factors continue systemic therapy and are reevaluated at six months. Treatment with nivolumab may continue for up to two years or until unacceptable toxicity. During the study, tumor tissue, blood, and stool samples are collected at baseline, three months, and six months for research purposes. Outcomes being measured include overall survival with a minimum follow-up of three years, progression-free survival, response rates, treatment-related side effects, surgical complications, and various biomarker analyses. Participants will be monitored regularly throughout treatment and follow-up, with the study lasting through to the planned completion date in 2031.

CONDITIONS

Brief Title

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

Research Team

N

Niels Fristrup, MD PhD

A

Ane Iversen, MD PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here